Company Profile
Carisma Therapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- CARM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.00 USD (0.00%)
Close
Last updated: September 17, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for CARM.
Company overview
Business overview
Carisma Therapeutics is a cell-therapy company focused on engineered macrophages and cancer immunotherapy. Its story centers on using a novel immune-cell approach to attack tumors.
Geographic Base and Sector Classification
Carisma is headquartered in the United States and listed on NASDAQ. It sits in cell therapy and oncology biotechnology.
Business Model Characteristics
The company depends on clinical validation, manufacturing feasibility, and capital support while it advances a narrow pipeline. Investors watch early data and platform differentiation.
Position Within the Biotechnology Landscape
Carisma occupies a specialized macrophage-cell-therapy niche within biotech. It is catalyst-sensitive because the platform still needs to prove itself clinically.
Future catalysts
- Carisma’s catalysts are macrophage-engineering programs and any strategic or clinical update that clarifies the company’s next path. The company still needs stronger human proof.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Carisma Therapeutics, Inc. (CARM)?
Carisma Therapeutics, Inc. (CARM) most recently closed at 0.00 USD, a 0.00% move versus the previous session.
What does Carisma Therapeutics, Inc. do?
Carisma Therapeutics is a cell-therapy company focused on engineered macrophages and cancer immunotherapy. Its story centers on using a novel immune-cell approach to attack tumors.
On which exchange is CARM stock listed?
Carisma Therapeutics, Inc. (CARM) is associated with NASDAQ, United States, Biopharma.
What is Carisma?
Carisma’s catalysts are macrophage-engineering programs and any strategic or clinical update that clarifies the company’s next path.
Which conditions is Carisma Therapeutics, Inc. targeting with Carisma?
Carisma Therapeutics, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Carisma Therapeutics, Inc. describe recent progress with Carisma?
Carisma’s catalysts are macrophage-engineering programs and any strategic or clinical update that clarifies the company’s next path.
What is Therapeutics?
Carisma Therapeutics is a cell-therapy company focused on engineered macrophages and cancer immunotherapy.
What should investors watch for with Therapeutics?
Carisma’s catalysts are macrophage-engineering programs and any strategic or clinical update that clarifies the company’s next path. The company still needs stronger human proof.